Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2025-03.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 93

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 94
Clinical effects of yeast derived recombinant methionyl growth hormone in growth hormone deficiency.

Journal of the Korean Pediatric Society 1991;34(3):334-339.
Published online March 31, 1991.
Clinical effects of yeast derived recombinant methionyl growth hormone in growth hormone deficiency.
Byung Churl Lee
Department of Pediatrics, Catholic University Medical College, Seoul, Korea
국내에서 합성된 성장호르몬의 성장호르몬 결핍증 환아에 대한 치료 효과
이병철
가톨릭의과대학 소아과학교실
Received: 27 January 1991   • Accepted: 5 February 1991
Abstract
Since the success of human growth hormone (hGH) synthesis by recombinant DNA technology, these GH products are used in the treatment of growth hormone deficiency. Recently, methionyl-GH has been produced in the yeast, Saccharomyces cerevisiae 2150 by the use of a recombinant method. In this paper, the clinical efficacy and. immunogenicity of this GH was studied during therapy of 1 year in 20 children with naive GH deficiency. The subjects of this study are aged 4.5-14.3 years, diagnosed by failure of plasma GH to respond to insulin-induced hypoglycemia, arginine and/or clonidine loading and height below-2 standard deviation of mean for their chronological age. Each patient received GH 0.45 IU/kg/week intramusculary in 3 divided dose. During treatment, vital signs, height, body weight and bone age were checked. Blood count, urinalysis, blood chemistry and measurement of thyroid hormone were performed before and every 3 months, measurement of IGF-I were performed before and every 6 months and assay of antibody against hGH were performed before and 1 year treatment. The height velocity during 1 year treatment ranged from 5.1 to 12.4 cm/year, with a mean of 7. 8±1.9 cm/year. Their previous height velocity was 2.9+1.1 cm/year. The increments in height age and bone age were 1.4±0.3 and 1.2±0.2 year during 1 year treat- ment. During treatment, mean plasma IGF-I levels rose significantly in the all patients. Antibody against hGH was observed in 3 of the 16 patients (18.8%) and unwanted side effects were not observed in any of the 20 patients. These results suggest that this yeast derived recombinant methionyl growth hormone is very effective in stimulating linear growth in growth hormone deficiency.
Key Words: Growth hormone, growth hormone deficiency


METRICS Graph View
  • 1,989 View
  • 35 Download